Cargando…

PI3Kα inhibitor impairs AKT phosphorylation and synergizes with novel angiogenesis inhibitor AL3810 in human hepatocellular carcinoma

Detalles Bibliográficos
Autores principales:	Xie, Qin, Chi, Shuaishuai, Fang, Yanfen, Sun, Yiming, Meng, Linghua, Ding, Jian, Chen, Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010115/ https://www.ncbi.nlm.nih.gov/pubmed/33785733 http://dx.doi.org/10.1038/s41392-021-00522-6

Ejemplares similares

Is PDGFR an important target for E-3810?
por: Damia, Giovanna, et al.
Publicado: (2012)

The PI3K inhibitor copanlisib synergizes with sorafenib to induce cell death in hepatocellular carcinoma
por: Ye, Liangtao, et al.
Publicado: (2019)

Quantitative Chemical Proteomics Identifies Novel Targets of the Anti-cancer Multi-kinase Inhibitor E-3810
por: Colzani, Mara, et al.
Publicado: (2014)

AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti-angiogenic and anti-tumour activity via targeting VEGFR, FGFR and PDGFR
por: Zhou, Yuanfeng, et al.
Publicado: (2012)

A pentapeptide enabled AL3810 liposome-based glioma-targeted therapy with immune opsonic effect attenuated
por: Li, Jinyang, et al.
Publicado: (2021)

A Phase Ib Study of Lucitanib (AL3810) in a Cohort of Patients with Recurrent and Metastatic Nasopharyngeal Carcinoma
por: Zhang, Yang, et al.
Publicado: (2022)

The onset of PI3K‐related vascular malformations occurs during angiogenesis and is prevented by the AKT inhibitor miransertib
por: Kobialka, Piotr, et al.
Publicado: (2022)

Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth
por: Sweetlove, Melanie, et al.
Publicado: (2015)

PI3K/AKT/mTOR Pathway in Angiogenesis
por: Karar, Jayashree, et al.
Publicado: (2011)

Hydroxychloroquine synergizes with the PI3K inhibitor BKM120 to exhibit antitumor efficacy independent of autophagy
por: Peng, Xin, et al.
Publicado: (2021)

PI3K/Akt/mTOR inhibitors in breast cancer
por: Lee, Joycelyn JX, et al.
Publicado: (2015)

Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells
por: Nepstad, Ina, et al.
Publicado: (2019)

The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma
por: Amirouchene-Angelozzi, Nabil, et al.
Publicado: (2016)

OMRT-7. Angiogenesis inhibitors strongly synergize with therapeutics targeting tumor metabolism
por: Khadka, Sunada
Publicado: (2021)

Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092
por: Yu, Yi, et al.
Publicado: (2015)

Roxarsone induces angiogenesis via PI3K/Akt signaling
por: Wang, Yujing, et al.
Publicado: (2016)

Correction to: Hydroxychloroquine synergizes with the PI3K inhibitor BKM120 to exhibit antitumor efficacy independent of autophagy
por: Peng, Xin, et al.
Publicado: (2021)

K-ras/PI3K-Akt Signaling Is Essential for Zebrafish Hematopoiesis and Angiogenesis
por: Liu, Lihui, et al.
Publicado: (2008)

Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma
por: Berretta, Massimiliano, et al.
Publicado: (2016)

Comparing PI3K/Akt Inhibitors Used in Ovarian Cancer Treatment
por: Wu, Yi-Hui, et al.
Publicado: (2020)

RIDR-PI-103, ROS-activated prodrug PI3K inhibitor inhibits cell growth and impairs the PI3K/Akt pathway in BRAF and MEK inhibitor-resistant BRAF-mutant melanoma cells
por: Patel, Hima, et al.
Publicado: (2023)

Apatinib suppresses the migration, invasion and angiogenesis of hepatocellular carcinoma cells by blocking VEGF and PI3K/AKT signaling pathways
por: Song, Jifu, et al.
Publicado: (2021)

The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer
por: Ma, Liying, et al.
Publicado: (2020)

Insight into resistance mechanisms of AZD4547 and E3810 to FGFR1 gatekeeper mutation via theoretical study
por: Liang, Donglou, et al.
Publicado: (2017)

The Akt Inhibitor ISC-4 Synergizes with Cetuximab in 5-FU-Resistant Colon Cancer
por: Allen, Joshua E., et al.
Publicado: (2013)

The AKT Inhibitor MK-2206 is Cytotoxic in Hepatocarcinoma Cells Displaying Hyperphosphorylated AKT-1 and Synergizes with Conventional Chemotherapy
por: Simioni, Carolina, et al.
Publicado: (2013)

Discovery of a New CDK4/6 and PI3K/AKT Multiple Kinase Inhibitor Aminoquinol for the Treatment of Hepatocellular Carcinoma
por: Xia, Zhong-Kun, et al.
Publicado: (2021)

Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells
por: Shingu, Takashi, et al.
Publicado: (2016)

PI3K/AKT/PTEN Signaling as a Molecular Target in Leukemia Angiogenesis
por: Okumura, Naoko, et al.
Publicado: (2012)

BET bromodomain inhibitors synergize with ATR inhibitors in melanoma
por: Veppil Muralidharan, Somsundar, et al.
Publicado: (2017)

BET bromodomain inhibitors synergize with ATR inhibitors in melanoma
por: Muralidharan, Somsundar Veppil, et al.
Publicado: (2017)

Mitochondrial Complex I Inhibitors and Forced Oxidative Phosphorylation Synergize in Inducing Cancer Cell Death
por: Palorini, Roberta, et al.
Publicado: (2013)

Correction to: The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer
por: Ma, Liying, et al.
Publicado: (2021)

Inhibitors of the PI3K/Akt/mTOR Pathway in Prostate Cancer Chemoprevention and Intervention
por: Roudsari, Nazanin Momeni, et al.
Publicado: (2021)

Characterization, management, and risk factors of hyperglycemia during PI3K or AKT inhibitor treatment
por: Liu, Dazhi, et al.
Publicado: (2022)

Identification of Potential Kinase Inhibitors within the PI3K/AKT Pathway of Leishmania Species
por: Ochoa, Rodrigo, et al.
Publicado: (2021)

New Insights into PI3K Inhibitor Design using X-ray Structures of PI3Kα Complexed with a Potent Lead Compound
por: Yang, Xiuyan, et al.
Publicado: (2017)

Correction: The Akt Inhibitor ISC-4 Synergizes with Cetuximab in 5-FU-Resistant Colon Cancer
por: Allen, Joshua E., et al.
Publicado: (2013)

A high-throughput drug combination screen identifies an anti-glioma synergism between TH588 and PI3K inhibitors
por: Chen, Zhen, et al.
Publicado: (2020)

NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations
por: PARK, EUNJU, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_n8ldctg9qf8unbtnlisrsnh5cr